Literature DB >> 10699613

Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.

W J Catalona1, A W Partin, K M Slawin, C K Naughton, M K Brawer, R C Flanigan, J P Richie, A Patel, P C Walsh, P T Scardino, P H Lange, J B deKernion, P C Southwick, K G Loveland, R E Parson, G H Gasior.   

Abstract

OBJECTIVES: In predominately white populations, measurement of the percentage of free prostate-specific antigen (%fPSA) has been shown to enhance the specificity of total PSA testing for prostate cancer while maintaining high sensitivity and to aid in prostate cancer staging. This study evaluated whether the %fPSA cutoff that maintained a 95% sensitivity in a white population yielded the same sensitivity and specificity in a black population and whether %fPSA was useful in predicting postoperative pathologic features in blacks.
METHODS: We evaluated 647 white and 79 black men, prospectively enrolled at prostate cancer screening and surgical referral centers. Subjects were 50 to 75 years old with digital rectal examination findings that were not suspicious for prostate cancer and total PSA values between 4.0 and 10.0 ng/mL. All had undergone needle biopsy of the prostate. Hybritech's Tandem total and free PSA assays were used.
RESULTS: Ninety-five percent sensitivity was attained with a %fPSA cutoff of 25% in both races. Use of this cutoff could have avoided unnecessary biopsies in 20% of white and 17% of black subjects (P = 0.69). In receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) for %fPSA was significantly higher than for total PSA in both blacks (0.76 versus 0.56, P <0.01) and whites (0.70 versus 0.54, P <0.001). In both races, higher %fPSA values indicated a lower risk of cancer and also predicted favorable pathologic features in radical prostatectomy specimens.
CONCLUSIONS: A 25% fPSA cutoff detected 95% of cancers and reduced unnecessary biopsies in both races. Higher %fPSA values were associated with favorable postoperative histopathologic findings in both races.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10699613     DOI: 10.1016/s0090-4295(99)00547-6

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  7 in total

Review 1.  Liquid biomarkers for early detection of prostate cancer and summary of available data for their use in African-American men.

Authors:  Grant M Henning; Gerald L Andriole; Eric H Kim
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-04       Impact factor: 5.554

2.  Contributions of Social Factors to Disparities in Prostate Cancer Risk Profiles among Black Men and Non-Hispanic White Men with Prostate Cancer in California.

Authors:  David J Press; Salma Shariff-Marco; Daphne Y Lichtensztajn; Diane Lauderdale; Adam B Murphy; Pushkar P Inamdar; Mindy C DeRouen; Ann S Hamilton; Juan Yang; Katherine Lin; Donald Hedeker; Christopher A Haiman; Iona Cheng; Scarlett Lin Gomez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-30       Impact factor: 4.254

3.  Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml.

Authors:  Rui Chen; Yiran Huang; Xiaobing Cai; Liping Xie; Dalin He; Liqun Zhou; Chuanliang Xu; Xu Gao; Shancheng Ren; Fubo Wang; Lulin Ma; Qiang Wei; Changjun Yin; Ye Tian; Zhongquan Sun; Qiang Fu; Qiang Ding; Junhua Zheng; Zhangqun Ye; Dingwei Ye; Danfeng Xu; Jianquan Hou; Kexin Xu; Jianlin Yuan; Xin Gao; Chunxiao Liu; Tiejun Pan; Yinghao Sun
Journal:  PLoS One       Date:  2015-06-19       Impact factor: 3.240

4.  Percent free prostate-specific antigen is effective to predict prostate biopsy outcome in Chinese men with prostate-specific antigen between 10.1 and 20.0 ng ml(-1).

Authors:  Rui Chen; Li-Qun Zhou; Xiao-Bing Cai; Li-Ping Xie; Yi-Ran Huang; Da-Lin He; Xu Gao; Chuan-Liang Xu; Qiang Ding; Qiang Wei; Chang-Jun Yin; Shan-Cheng Ren; Fu-Bo Wang; Ye Tian; Zhong-Quan Sun; Qiang Fu; Lu-Lin Ma; Jun-Hua Zheng; Zhang-Qun Ye; Ding-Wei Ye; Dan-Feng Xu; Jian-Quan Hou; Ke-Xin Xu; Jian-Lin Yuan; Xin Gao; Chun-Xiao Liu; Tie-Jun Pan; Ying-Hao Sun
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

5.  Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0-10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium.

Authors:  Rui Chen; Liping Xie; Xiaobing Cai; Yiran Huang; Liqun Zhou; Lulin Ma; Xu Gao; Chuanliang Xu; Shancheng Ren; Pengfei Shao; Danfeng Xu; Kexin Xu; Zhangqun Ye; Chunxiao Liu; Dingwei Ye; Li Lu; Qiang Fu; Jianquan Hou; Jianlin Yuan; Dalin He; Tie Zhou; Fubo Wang; Biming He; Yinghao Sun
Journal:  Asian J Urol       Date:  2015-04-16

6.  Evaluation and multi-institutional validation of a novel urine biomarker lncRNA546 to improve the diagnostic specificity of prostate cancer in PSA gray-zone.

Authors:  Fei Liu; Xiaolei Shi; Fangming Wang; Sujun Han; Dong Chen; Xu Gao; Linhui Wang; Qiang Wei; Nianzeng Xing; Shancheng Ren
Journal:  Front Oncol       Date:  2022-08-12       Impact factor: 5.738

7.  The value of percentage free prostate specific antigen (PSA) in the detection of prostate cancer among patients with intermediate levels of total PSA (4.0-10.0 ng/mL) in Nigeria.

Authors:  E V Ezenwa; K H Tijani; E A Jeje; O O Soriyan; M A Ogunjimi; R W Ojewola; O I Ajie; A R El-Nahas
Journal:  Arab J Urol       Date:  2012-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.